BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20007331)

  • 1. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon.
    Turriziani O; Montagna C; Falasca F; Bucci M; Russo G; Lichtner M; Sobze MS; Vullo V; Pistello M; Antonelli G
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1729-33. PubMed ID: 22214532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
    Ceccherini-Silberstein F; Malet I; Fabeni L; Dimonte S; Svicher V; D'Arrigo R; Artese A; Costa G; Bono S; Alcaro S; Monforte Ad; Katlama C; Calvez V; Antinori A; Marcelin AG; Perno CF
    J Antimicrob Chemother; 2010 Nov; 65(11):2305-18. PubMed ID: 20817922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
    Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
    Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.
    Nouhin J; Donchai T; Hoang KT; Ken S; Kamkorn J; Tran T; Ayouba A; Peeters M; Chaix ML; Lien TX; Nerrienet E; Ngo-Giang-Huong N
    Infect Genet Evol; 2011 Jan; 11(1):38-43. PubMed ID: 21094281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.
    Charpentier C; Laureillard D; Piketty C; Tisserand P; Batisse D; Karmochkine M; Si-Mohamed A; Weiss L
    AIDS; 2010 Mar; 24(6):867-73. PubMed ID: 20160635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
    Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
    Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
    Delaugerre C
    Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases.
    Malet I; Soulie C; Tchertanov L; Derache A; Amellal B; Traore O; Simon A; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
    J Med Virol; 2008 May; 80(5):754-61. PubMed ID: 18360887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An HIV-1 integrase genotype assay for the detection of drug resistance mutations.
    Hearps AC; Greengrass V; Hoy J; Crowe SM
    Sex Health; 2009 Dec; 6(4):305-9. PubMed ID: 19917199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.